Aggarwal 2018.
Methods | Method of randomisation not clear. |
Participants | 105 survivors of paediatric ALL or Hodgkin lymphoma (mean age at follow‐up 27.7 years; N = 47 females and N = 58 males; stage of disease at diagnosis nm) treated with doxorubicin (cumulative dose 100 to 360 mg/m2; peak dose (i.e. maximal dose received in 1 week) nm; infusion duration nm). Prior anthracycline therapy nm. Prior cardiac radiotherapy nm. Prior cardiac dysfunction nm. |
Interventions | Dexrazoxane (ratio to doxorubicin 10:1; timing in relation to anthracycline nm) (N = 57) versus no cardioprotective intervention (N = 48). |
Outcomes | Heart failure (i.e. different abnormalities on speckle tracking echocardiography); in the abstract no dichotomous results were provided. |
Notes | Unclear if this is an ongoing or completed study. Length of follow‐up 16.5 years since cancer diagnosis. Mean cumulative anthracycline dose in the dexrazoxane group was 282 mg/m2 and in the control group 275 mg/m2. Mean age at echocardiogram of the dexrazoxane group was 27.3 years and of the control group 28.1 years. |